33.81
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$33.69
Offen:
$33.07
24-Stunden-Volumen:
2.50M
Relative Volume:
1.11
Marktkapitalisierung:
$5.36B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-307.36
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
-2.14%
1M Leistung:
-7.89%
6M Leistung:
-22.17%
1J Leistung:
+38.79%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Vergleichen Sie TGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TGTX
Tg Therapeutics Inc
|
33.81 | 5.35B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TG Therapeutics (TGTX) Margin Miss Challenges Growth-Driven Profitability Narrative - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Given New $49.00 Price Target at JPMorgan Chase & Co. - MarketBeat
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised - TradingView
TG Therapeutics (TGTX): Exploring Valuation as Growth Prospects Spark Investor Interest - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Beats Estimates By $2.19 EPS - MarketBeat
Tools to assess TG Therapeutics Inc.’s risk profileMarket Activity Report & Safe Investment Capital Preservation Plans - newser.com
TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2025 Earnings Call Transcript - Insider Monkey
Hussman Strategic Advisors Inc. Grows Position in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics: Q3 Earnings Snapshot - theheraldreview.com
HC Wainwright Predicts Reduced Earnings for TG Therapeutics - MarketBeat
Will TG Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - newser.com
How TG Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Sector Moves & Reliable Entry Point Alerts - newser.com
Building trade automation scripts for TG Therapeutics Inc.July 2025 Sentiment & Verified Momentum Watchlists - newser.com
How to build a dashboard for TG Therapeutics Inc. stockJuly 2025 Movers & Weekly High Return Opportunities - newser.com
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $585M while advancing subcutaneous pipeline - MSN
Is now a turning point for TG Therapeutics Inc.Short Setup & Daily Risk Controlled Trade Plans - newser.com
TG Therapeutics Inc (TGTX) Q3 2025 Earnings Call Highlights: Rec - GuruFocus
TG Therapeutics Inc (TGTX) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... - Yahoo Finance
TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics, Inc. Raises Earnings Guidance for the Year 2025 - MarketScreener
TG Therapeutics (TGTX) Reports Strong Q3 2025 Results Driven by BRIUMVI - GuruFocus
TG Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Transcript : TG Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
TGTX: JP Morgan Raises Price Target to $49, Maintains Overweight Rating | TGTX Stock News - GuruFocus
Earnings call transcript: TG Therapeutics Q3 2025 beats EPS forecast, stock dips - Investing.com Canada
Earnings call transcript: TG Therapeutics Q3 2025 beats EPS forecast, stock dips By Investing.com - Investing.com South Africa
TG Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
TG Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug - Stocktwits
TG Therapeutics (TGTX) Reports Strong Q3, Raises 2025 Revenue Gu - GuruFocus
TG Therapeutics Inc (TGTX) Reports Q3 2025 Revenue of $161.7 Mil - GuruFocus
TG Therapeutics (TGTX) Increases 2025 BRIUMVI Revenue Forecast - GuruFocus
TG Therapeutics (TGTX) Surpasses Q3 Revenue Expectations and Exp - GuruFocus
TG Therapeutics Q3 Earnings: $390.9M Net Income, Beats ForecastsNews and Statistics - IndexBox
TG Therapeutics Q3 Net Income, Revenue Rise; Raises 2025 Revenue Guidance - MarketScreener
Earnings Flash (TGTX) TG Therapeutics, Inc. Reports Q3 Revenue $161.7M, vs. FactSet Est of $152.1M - MarketScreener
TG Therapeutics Q3 revenue up on strong demand, raises 2025 forecast - TradingView
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance - Yahoo Finance
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update - MarketScreener
Analyzing recovery setups for TG Therapeutics Inc. investorsJuly 2025 Price Swings & Short-Term Swing Trade Alerts - newser.com
What dividend safety score for TG Therapeutics Inc. stockTrade Performance Summary & Risk Controlled Swing Alerts - newser.com
TG Therapeutics Builds On BRIUMVI's Momentum Ahead Of Q3 Earnings And 2027 Launch Plans - RTTNews
Can TG Therapeutics Inc. stock resist market sell offsWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Is it time to cut losses on TG Therapeutics Inc.Dividend Hike & Daily Chart Pattern Signal Reports - newser.com
Is TG Therapeutics Inc. stock oversold or undervaluedJuly 2025 Earnings & Precise Buy Zone Identification - newser.com
How TG Therapeutics Inc. (NKB2) stock trades under stagflationQuarterly Growth Report & Verified Trade Idea Suggestions - newser.com
How to escape a deep drawdown in TG Therapeutics Inc.Breakout Watch & Daily Chart Pattern Signal Reports - newser.com
Is TG Therapeutics Inc. stock a good choice for value investorsJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Will TG Therapeutics Inc. stock outperform value stocksJuly 2025 Reactions & Short-Term High Return Strategies - newser.com
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):